Cooperative expression of junctional adhesion molecule-C and -B supports growth and invasion of glioma
Brain invasion is a biological hallmark of glioma that contributes to its aggressiveness and limits the potential of surgery and irradiation. Deregulated expression of adhesion molecules on glioma cells is thought to contribute to this process. Junctional adhesion molecules (JAMs) include several Ig...
Gespeichert in:
Veröffentlicht in: | Glia 2010-04, Vol.58 (5), p.524-537 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Brain invasion is a biological hallmark of glioma that contributes to its aggressiveness and limits the potential of surgery and irradiation. Deregulated expression of adhesion molecules on glioma cells is thought to contribute to this process. Junctional adhesion molecules (JAMs) include several IgSF members involved in leukocyte trafficking, angiogenesis, and cell polarity. They are expressed mainly by endothelial cells, white blood cells, and platelets. Here, we report JAM‐C expression by human gliomas, but not by their normal cellular counterpart. This expression correlates with the expression of genes involved in cytoskeleton remodeling and cell migration. These genes, identified by a transcriptomic approach, include poliovirus receptor and cystein‐rich 61, both known to promote glioma invasion, as well as actin filament associated protein, a c‐Src binding partner. Gliomas also aberrantly express JAM‐B, a high affinity JAM‐C ligand. Their interaction activates the c‐Src proto‐oncogene, a central upstream molecule in the pathways regulating cell migration and invasion. In the tumor microenvironment, this co‐expression may thus promote glioma invasion through paracrine stimuli from both tumor cells and endothelial cells. Accordingly, JAM‐C/B blocking antibodies impair in vivo glioma growth and invasion, highlighting the potential of JAM‐C and JAM‐B as new targets for the treatment of human gliomas. © 2009 Wiley‐Liss, Inc. |
---|---|
ISSN: | 0894-1491 1098-1136 |
DOI: | 10.1002/glia.20941 |